Table 1. Represents clinical characteristics of the patients recruited in this study.

Variables		(A) Tissue cohort (n=115)					(B) Serum cohort (n=65)
		Case (n=85)	Control (n=30)	Relative expression of miR-34a (2-ΔΔCT)	Relative expression of let-7f (2-ΔΔCT)	Relative expression of miR-31 (2-ΔΔCT)	Case (n=50)	Relative expression of miR-34a (2-ΔΔCT)	Relative expression of let-7f (2-ΔΔCT)	Relative expression of miR-31 (2-ΔΔCT)
Age, No. (%)
	<45	26 (37.1)	16 (53.3)	−6.39±3.66	−5.29±3.60	−5.87±2.54	14 (28.0)	−5.63±2.57	−3.01±2.92	−2.76±2.08
	≥45	44 (62.8)	14 (46.6)	−6.30±3.91	−5.40±4.85	−6.65±3.63	36 (72.0)	−5.88±2.80	−6.94±4.15	−4.97±3.62
	p-value			ns	ns	ns		ns	<0.001	ns
Histological type, No. (%)
	Mucinous	14 (16.5)	-	−6.15±3.12	−3.71±3.31	−7.03±3.40	8 (22.8)	−4.88±1.28	−7.05±4.77	−3.71±3.25
	Serous	50 (58.8)	-	−6.52±4.34	−6.30±4.93	−6.36±3.04	15 (42.8)	−6.74±2.80	−6.35±4.65	−4.28±3.64
	Clear cell	10 (11.5)	-	−5.58±3.38	−4.10±3.12	−8.34±4.57	6 (17.1)	−5.32±2.82	−5.71±3.88	−7.38±1.86
	Endometrioid	11 (12.9)	-	−6.36±2.42	−5.03±4.34	−4.28±2.18	6 (17.1)	−3.84±2.99	−3.63±1.81	−2.82±2.13
	Other	-	-	-	-	-	-	-	-	-
	p-value			ns	<0.05	<0.05		<0.05	<0.05	<0.05
Distant metastasis, No. (%)
	Absent	40 (47.0)	-	−5.19±3.36	−3.56±2.66	−5.35±2.35	14 (40.0)	−4.42±1.66	−5.55±3.88	−3.00±3.08
	Present	45 (52.9)	-	−7.22±3.89	−7.11±5.14	−7.40±3.76	21 (60.0)	−6.74±2.86	−6.46±4.68	−5.25±3.34
	p-value			<0.005	<0.005	<0.005		<0.005	ns	<0.05
FIGO stage, No. (%)
	Stage I-II	41 (48.2)	-	−5.19±3.36	−3.56±2.66	−5.35±2.35	20 (57.1)	−4.24±1.72	−8.37±4.92	−6.43±4.14
	Stage III-IV	44 (51.7)	-	−7.22±3.89	−7.11±5.14	−7.40±3.76	15 (42.8)	−6.85±2.78	−4.15±2.60	−2.96±1.80
	p-value			<0.005	<0.005	<0.005		<0.005	<0.005	0.0071
Menopause status, No. (%)
	Yes	52 (61.1)	-	−7.25±4.17	−5.89±5.07	−7.22±3.64	22 (62.8)	−6.26±3.02	−6.83±4.19	−4.82±3.36
	No	33 (38.8)	-	−4.87±2.63	−4.52±3.30	−5.11±2.26	13 (37.1)	−5.07±1.99	−4.35±3.90	−3.58±3.40
	p-value			<0.005	ns	<0.05		ns	<0.05	ns
Serum CA125 (U/mL)		184±329.1	33.8±61.4				172±352.4

ns, not significant.